HR+/HER2− breast cancer patients showed the highest locoregional recurrence-free survival rate, whereas HR−/HER2+ patients had the lowest locoregional recurrence-free survival rate (P < 0.001; Figure 1A). The gene discussed is ERBB2; the disease is breast carcinoma.